Defective taxane stimulation of epirubicinol formation in the human heart: Insight into the cardiac tolerability of epirubicin-taxane chemotherapies

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 2, 2007, Pages 790-800

  Salvatorelli, Emanuela ^a   Menna, Pierantonio ^a   Gianni, Luca ^b   Minotti, Giorgio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALDEHYDE REDUCTASE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CREMOPHOR; DOCETAXEL; DOXORUBICIN; DRUG METABOLITE; DRUG VEHICLE; EPIRUBICIN; EPIRUBICINOL; PACLITAXEL; POLYSORBATE 80; REACTIVE OXYGEN METABOLITE; TAXANE DERIVATIVE;

ADULT; ARTICLE; CARDIOTOXICITY; CELL ISOLATION; CONTROLLED STUDY; CYTOSOL; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; HEART; HEART STIMULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC AGENTS; CYTOSOL; DOXORUBICIN; EPIRUBICIN; FEMALE; FLUORENES; HEART; HUMANS; HYDANTOINS; HYDROGEN PEROXIDE; MALE; MIDDLE AGED; MYOCARDIUM; PACLITAXEL; REACTIVE OXYGEN SPECIES; TAXOIDS;

EID: 33846425322     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.116160     Document Type: Article

References (39)

1. Barski OA, Gabbay KH, Grimshaw CE, and Bohren KM (1995) Mechanism of human aldehyde reductase: characterization of the active site pocket. Biochemistry 34:11264-112675.
2. Bonadonna G, Gianni L, Santoro A, Bonfante V, Bidoli P, Casali P, Demicheli R, and Valagussa P (1993) Drugs ten years later: epirubicin. Ann Oncol 4:359-369.
3. Charlier HA Jr, Olson RD, Thornock CM, Mercer WK, Olson DR, Broyles TS, Muhlestein DJ, Larson CL, Cusack BJ, and Shadle SE (2005) Investigations of calsequestrin as a target for anthracyclines: comparison of functional effects of daunorubicin, daunorubicinol, and trifluoperazine. Mol Pharmacol 67:1505-1512.
4. D'Incalci M, Schuller J, Colombo T, Zucchetti M, and Riva A (1998) Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. Semin Oncol 25 (Suppl 13):16-20.
5. Esposito M, Venturini M, Vannozzi MO, Tolino G, Lunari G, Garrone O, Angiolini C, Viale M, Bersasaglio M, Del Mastro L, et al. (1999) Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. J Clin Oncol 17:1132-1140.
6. Finlay GJ and Baguley BC (2000) Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Cancer Chemother Pharmacol 45:417-422.
7. Forrest GL, Gonzalez B, Tseng W, Li X, and Mann J (2000) Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 60:5158-5164.
8. Gambliel HA, Burke BE, Cusack BJ, Walsh GM, Zhang YL, Mushlin PS, and Olson RD (2002) Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. Biochem Biophys Res Commun 291:433-438.
9. Gennari A, Salvadori B, Donati S, Bengala C, Orlandini C, Danesi R, Del Tacca M, Bruzzi P, and Conte PF (1999) Cardiotoxicity of epirubicin/paclitaxel- containing regimens: role of cardiac risk factors. J Clin Oncol 17:3596-3602.
10. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741.
11. Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A, et al. (2005) Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 11:8715-8721.
12. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, et al. (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699.
13. Gianni L, Vigano' L, Locatelli A, Capri G, Giani A, Tarenzi E, and Bonadonna G (1997) Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15:1906-1915.
14. Glück S (2005) Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin. Oncologist 10:780-791.
15. Grasselli G, Vigano L, Capri G, Locatelli A, Tarenzi E, Spreafico C, Bertuzzi A, Giani A, Materazzo C, Cresta S, et al. (2001) Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. J Clin Oncol 19:2222-2231.
16. Holleran JL, Fourcade J, Egorin MJ, Eiseman JL, Parise RA, Musser SM, White KD, Covey JM, Forrest GL, and Pan S-S (2004) In vitro metabolism of the phosphatidylinositol 3-kinase inhibitor, wortmannin, by carbonyl reductase. Drug Metab Dispos 32:490-496.
17. Innocenti F, Iyer l, Ramirez J, Green MD, and Ratain MJ (2001) Epirubicin glucuronidation is catalyzed by human UDP glucuronosyltransferase 2B7. Drug Metab Dispos 29:686-692.
18. Loos WJ, Baker SD, Verweij J, Boonstra JG, and Sparreboom A (2003) Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther 74:364-371.
19. Maessen PA, Mross KB, Pinedo HM, and van der Vijgh WJ (1987) Metabolism of epidoxorubicin in animals: absence of glucuronidation. Cancer Chemother Pharmacol 20:85-87.
20. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, et al. (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313.
21. Menna P, Salvatorelli E, Giampietro R, Liberi G, Teodori G, Calafiore AM, and Minotti G (2002) Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines. Chem Res Toxicol 15:1179-1189.
22. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004a) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229.
23. Minotti G, Recalcati S, Menna P, Salvatorelli E, Corna G, and Cairo G (2004b) Doxorubicin cardiotoxicity and the control of iron metabolism: quinone dependent and independent mechanisms. Methods Enzymol 378:340-361.
24. Mylari BL, Beyer TA, and Siegel TW (1991) A highly specific aldose reductase inhibitor ethyl 1-benzyl-3-hydroxy-25H-oxopyrrole-4-carboxylate and its congeners. J Med Chem 34:1011-1018.
25. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, et al. (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968-975.
26. Nabholtz JM, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Vogel C, Weaver C, Walley B, Martin M, Chap L, et al. (2002) Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 21:141A
27. Ng SSW, Figg WD, and Sparreboom A (2004) Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res 64:821-824.
28. Olson RD, Mushlin PS, Brenner DE, Fleischer S, Chang BK, Cusack BJ, and Boucek RJ Jr (1988) Doxorubicin cardiotoxicity may be due to its metabolite, doxorubicinol. Proc Natl Acad Sci USA 85:3585-3589.
29. Pagani O, Sessa C, Nole F, Crivellari D, Lombardi D, Thurlimann B, Hess D, Borner M, Bauer J, Martinelli G, et al. (2000) Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Ann Oncol 11:985-991.
30. Perotti S, Cresta G, Grasselli G, Capri G, Minotti G, and Gianni L (2003) Cardiotoxic effects of anthracycline-taxane combinations. Expert Opin Drug Saf 2:59-71.
31. Rischin D, Ackland SP, Smith J, Garg MB, Clarke S, Millward MJ, Toner GC, and Zalcberg J (2002) Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics. Ann Oncol 13:1810-1818.
32. Rota C, Fann YC, and Mason RP (1999) Phenoxyl free radical formation during the oxidation of the fluorescent dye 2′,7′- dichlorofluorescein by horseradish peroxidase. Possible consequences for oxidative stress measurements. J Biol Chem 274:28161-28168.
33. Salvatorelli E, Guarnieri S, Menna P, Liberi G, Calafiore AM, Mariggiò MA, Mordente A, Gianni L, and Minotti G (2006a) Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: relative importance of vesicular sequestration and impaired efficiency of electron addition. J Biol Chem 281:10990-11001.
34. Salvatorelli E, Menna P, Cascegna S, Liberi G, Calafiore A, Gianni L, and Minotti G (2006b) Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J Pharmacol Exp Ther 318:424-433.
35. Slupe A, Williams B, Larson C, Lee LM, Primbs T, Bruesch AJ, Bjorklund C, Warner DL, Peloquin J, Shadle SE, et al. (2005) Reduction of 13-deoxydoxorubicin and daunorubicinol anthraquinones by human carbonyl reductase. Cardiovasc Toxicol 5:365-376.
36. Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Vigano L, Locatelli A, de Vos AI, Nooter K, Stoter G, et al. (1998) Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 4:1937-1942.
37. Stewart DJ, Grewaal D, Green RM, Mikhael N, Goel R, Montpetit VA, and Redmond MD (1993) Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues. Anticancer Res 13:1945-1952.
38. ten Tije AK, Verweij J, Loos WJ, and Sparreboom A (2003) Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42:665-685.
39. Wielinga PR, Westerhoff HV, and Lankelma J (2000) The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells. Eur J Biochem 267:649-657.